PE20171256A1 - Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa - Google Patents
Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasaInfo
- Publication number
- PE20171256A1 PE20171256A1 PE2017001245A PE2017001245A PE20171256A1 PE 20171256 A1 PE20171256 A1 PE 20171256A1 PE 2017001245 A PE2017001245 A PE 2017001245A PE 2017001245 A PE2017001245 A PE 2017001245A PE 20171256 A1 PE20171256 A1 PE 20171256A1
- Authority
- PE
- Peru
- Prior art keywords
- particles
- alpha
- fraction
- weight
- lactose monohydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a una formulacion de polvo seco inhalable, que comprende particulas micronizadas del compuesto 1-(3-ciclopropilmetoxi-4-difluorometoxi-fenil)-2-(3,5-dicloro-1-oxi-piridin-4-il)-etil ester del acido (-)-3-ciclopropilmetoxi-4-metansulfonilamino-benzoico como enantiomero (-) ; y particulas de un vehiculo que comprende una mezcla de particulas gruesas que comprenden alfa-lactosa monohidrato que tienen un diametro de masa de 150 a 400 micrones, particulas finamente divididas que comprenden alfa-lactosa monohidrato que tienen un diametro medio de masa entre 1 y 6 micrones, y estearato de magnesio en donde dicho enantiomero (-) esta presente en una cantidad entre 100 y 800 microgramos por disparo de inhalador, en donde ademas la fraccion de microparticulas esta compuesto por 90 a 99,5% en peso de alfa-lactosa monohidrato y entre 0,5 y 10% en peso de estearato de magnesio, y la relacion entre la fraccion de microparticulas y la fraccion de particulas gruesas comprende entre 1:99% y 40:60% en peso. Dicha formulacion es un inhibidor de fosfodiesterasa-4, siendo util en el tratamiento de la EPOC
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171748 | 2010-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171256A1 true PE20171256A1 (es) | 2017-08-28 |
Family
ID=43262631
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001245A PE20171256A1 (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa |
| PE2013000155A PE20130601A1 (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000155A PE20130601A1 (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9132121B2 (es) |
| EP (2) | EP2600830B1 (es) |
| JP (1) | JP6004233B2 (es) |
| KR (1) | KR101805958B1 (es) |
| CN (2) | CN103052379A (es) |
| AR (1) | AR082443A1 (es) |
| AU (1) | AU2011287711B2 (es) |
| BR (1) | BR112013002506A2 (es) |
| CA (1) | CA2807256C (es) |
| CL (1) | CL2013000293A1 (es) |
| CO (1) | CO6690744A2 (es) |
| CY (1) | CY1120605T1 (es) |
| DK (1) | DK2600830T3 (es) |
| EA (2) | EA027692B1 (es) |
| ES (1) | ES2664175T3 (es) |
| GE (1) | GEP20156343B (es) |
| HR (1) | HRP20180717T1 (es) |
| HU (1) | HUE037620T2 (es) |
| IL (1) | IL224517B (es) |
| LT (1) | LT2600830T (es) |
| MA (1) | MA34449B1 (es) |
| ME (1) | ME03022B (es) |
| MX (1) | MX346424B (es) |
| MY (1) | MY179703A (es) |
| NO (1) | NO2600830T3 (es) |
| NZ (1) | NZ606548A (es) |
| PE (2) | PE20171256A1 (es) |
| PL (1) | PL2600830T3 (es) |
| PT (1) | PT2600830T (es) |
| RS (1) | RS57061B1 (es) |
| SG (1) | SG187258A1 (es) |
| SI (1) | SI2600830T1 (es) |
| TR (1) | TR201807012T4 (es) |
| UA (1) | UA112296C2 (es) |
| WO (1) | WO2012016889A2 (es) |
| ZA (1) | ZA201300870B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| JP2014518203A (ja) | 2011-06-06 | 2014-07-28 | キエスィ ファルマチェウティチ エス．ピー．エー． | ホスホジエステラーゼ阻害剤としての１−フェニル−２−ピリジニルアルキルアルコール誘導体 |
| CN111904962A (zh) | 2012-11-08 | 2020-11-10 | 理森制药股份公司 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
| ES2744542T3 (es) * | 2013-03-15 | 2020-02-25 | Robert I Henkin | Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| JP6458957B2 (ja) | 2013-10-22 | 2019-01-30 | チエシ ファルマスティスィ エス．ピー．エー． | Ｐｄｅ４阻害剤の製造方法 |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| CN106233141B (zh) | 2014-02-18 | 2018-08-21 | 罗伯特·I·汉金 | 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物 |
| EA201692456A1 (ru) * | 2014-07-09 | 2017-08-31 | Арвен Иладж Санайи Ве Тиджарет А.Ш. | Способ получения составов для ингаляции |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| KR101859752B1 (ko) * | 2017-09-13 | 2018-05-21 | 심원 | 조립식 열 저장 운반장치 |
| KR101859750B1 (ko) * | 2017-09-13 | 2018-05-21 | 제일에스엠피(주) | 고정식 열 저장 운반장치 |
| WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| WO2024062007A1 (en) * | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| WO2024062005A1 (en) * | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| WO2024062006A1 (en) * | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19841248A1 (de) | 1997-09-12 | 1999-04-29 | Fraunhofer Ges Forschung | Demonstrationseinrichtung in Form eines Lebewesens |
| DE59801018D1 (de) | 1997-09-16 | 2001-08-16 | Trench Switzerland Ag Basel | Spannungsteiler |
| HUP0200185A3 (en) | 1999-03-05 | 2006-07-28 | Chiesi Farma Spa | Improved powdery pharmaceutical compositions for inhalation |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US7744855B2 (en) | 2000-06-27 | 2010-06-29 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| EP1386630B1 (en) | 2002-07-31 | 2006-05-17 | CHIESI FARMACEUTICI S.p.A. | Powder inhaler |
| DE10255387A1 (de) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Tiotropium-haltige Pulverformulierung für die Inhalation |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1891001B1 (en) * | 2005-06-06 | 2010-05-05 | F. Hoffmann-Roche AG | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| JP2014518203A (ja) | 2011-06-06 | 2014-07-28 | キエスィ ファルマチェウティチ エス．ピー．エー． | ホスホジエステラーゼ阻害剤としての１−フェニル−２−ピリジニルアルキルアルコール誘導体 |
| JP6458957B2 (ja) | 2013-10-22 | 2019-01-30 | チエシ ファルマスティスィ エス．ピー．エー． | Ｐｄｅ４阻害剤の製造方法 |
-
2011
- 2011-07-27 CA CA2807256A patent/CA2807256C/en active Active
- 2011-07-27 SI SI201131448T patent/SI2600830T1/en unknown
- 2011-07-27 HU HUE11741172A patent/HUE037620T2/hu unknown
- 2011-07-27 PE PE2017001245A patent/PE20171256A1/es unknown
- 2011-07-27 NZ NZ606548A patent/NZ606548A/en unknown
- 2011-07-27 DK DK11741172.8T patent/DK2600830T3/en active
- 2011-07-27 EP EP11741172.8A patent/EP2600830B1/en active Active
- 2011-07-27 EA EA201690541A patent/EA027692B1/ru unknown
- 2011-07-27 MY MYPI2013000339A patent/MY179703A/en unknown
- 2011-07-27 PE PE2013000155A patent/PE20130601A1/es active IP Right Grant
- 2011-07-27 ME MEP-2018-101A patent/ME03022B/me unknown
- 2011-07-27 MA MA35635A patent/MA34449B1/fr unknown
- 2011-07-27 TR TR2018/07012T patent/TR201807012T4/tr unknown
- 2011-07-27 SG SG2013008107A patent/SG187258A1/en unknown
- 2011-07-27 CN CN2011800382903A patent/CN103052379A/zh active Pending
- 2011-07-27 PT PT117411728T patent/PT2600830T/pt unknown
- 2011-07-27 EP EP17176635.5A patent/EP3246016A1/en active Pending
- 2011-07-27 LT LTEP11741172.8T patent/LT2600830T/lt unknown
- 2011-07-27 GE GEAP201112988A patent/GEP20156343B/en unknown
- 2011-07-27 CN CN201710259305.8A patent/CN106890165A/zh active Pending
- 2011-07-27 PL PL11741172T patent/PL2600830T3/pl unknown
- 2011-07-27 EA EA201390049A patent/EA024922B1/ru unknown
- 2011-07-27 AU AU2011287711A patent/AU2011287711B2/en active Active
- 2011-07-27 WO PCT/EP2011/062872 patent/WO2012016889A2/en active Application Filing
- 2011-07-27 RS RS20180394A patent/RS57061B1/sr unknown
- 2011-07-27 JP JP2013522202A patent/JP6004233B2/ja active Active
- 2011-07-27 KR KR1020137002872A patent/KR101805958B1/ko active IP Right Grant
- 2011-07-27 MX MX2013001172A patent/MX346424B/es active IP Right Grant
- 2011-07-27 ES ES11741172.8T patent/ES2664175T3/es active Active
- 2011-07-27 UA UAA201302607A patent/UA112296C2/uk unknown
- 2011-07-27 NO NO11741172A patent/NO2600830T3/no unknown
- 2011-07-27 BR BR112013002506A patent/BR112013002506A2/pt not_active Application Discontinuation
- 2011-08-02 AR ARP110102782 patent/AR082443A1/es not_active Application Discontinuation
- 2011-08-02 US US13/195,885 patent/US9132121B2/en active Active
-
2013
- 2013-01-30 CL CL2013000293A patent/CL2013000293A1/es unknown
- 2013-01-31 IL IL224517A patent/IL224517B/en active IP Right Grant
- 2013-02-01 CO CO13019325A patent/CO6690744A2/es unknown
- 2013-02-01 ZA ZA2013/00870A patent/ZA201300870B/en unknown
-
2015
- 2015-08-07 US US14/820,939 patent/US9308200B2/en active Active
-
2018
- 2018-03-09 CY CY181100288T patent/CY1120605T1/el unknown
- 2018-05-09 HR HRP20180717TT patent/HRP20180717T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171256A1 (es) | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa | |
| AR070834A1 (es) | Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| ES2539612T3 (es) | Formulaciones de partículas en polvo seco que contienen dos o más principios activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vías respiratorias | |
| PH12015501404A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| PE20141964A1 (es) | Formulaciones farmaceuticas novedosas | |
| IN2014MN01754A (es) | ||
| HK1182619A1 (zh) | 用於局部給藥的螺-羥吲哚化合物的藥物組合物及其作為治療劑的用途 | |
| SG10201802116RA (en) | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol | |
| WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| MX341482B (es) | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. | |
| NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| PE20142441A1 (es) | Nueva dosificacion y formulacion | |
| MX2012007711A (es) | Compuestos de piruvamida como inhibidores de alergeno de peptidasa del grupo 1 de acaros del polvo. | |
| CL2009001759A1 (es) | Compuesto (4-(5-aminometil-2-fluorofenil)piperidin-1-il)(7-fluoro-1(2-metoxietil)-4-trifluorometoxi-1h-indol-3-il)metanona; forma cristalina a de la sal benzoato; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, tales como epoc, alergia,dermatitis atopica, entre otras. | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
| ES2609820T3 (es) | Inhaladores de polvo seco que comprenden un vehículo distinto de lactosa | |
| EP2758043A4 (en) | COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL | |
| PE20142444A1 (es) | Nueva composicion de alfentanilo para el tratamiento del dolor agudo | |
| TR200909792A2 (tr) | Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu | |
| TR200909793A2 (tr) | Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu. | |
| TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| TH159392A (es) | ||
| TR201903199T4 (tr) | Bir yağ asidiyle kaplı bir beta agonistin kristal mikropartikülleri. |